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ABSTRACT OF THE DISSERTATION
Efficacy of Cognitive Therapy
and Pharmacotherapy In Depression: A Meta-Analysis
by
Daniel B. Michel
Doctor of Psychology, Graduate Program in Psychology
Loma Linda University, December 2007
Dr. Kendal C. Boyd, Chairperson

A meta-analysis comparing the long-term effectiveness of
cognitive behavioral therapy (CBT)

and pharmacotherapy in

preventing relapse following treatment discontinuation was
performed using published studies of depressed participants.
Twenty-three articles met inclusionary criteria and were
included in the analyses. Weighted effect sizes and
moderators, treatment type, were calculated using
statistical analysis software. Initially,

fixed effects

models were applied to the data, but due to significant
between-group heterogeneity that could not be fully
explained by treatment type, mixed effect models were used
to account for the residual heterogeneity. Results indicated
that overall, depressed individuals treated to remission
with CBT evidence decreased relapse rates up to 104 weeks
post-treatment compared to those treated with
pharmacotherapy. This finding was specifically supported at

vi

52 weeks follow-up. However, while this finding was not
significant at 104 weeks, the clear trend was in support of
CBT. These findings have important implications for the
effective long-term management of the recurrent nature of
major depression.

Yll

Introduction

Of all the psychiatric disorders, depression ranks as
the most common, with more than 100 million people worldwide
developing clinically significant depression each year
(Gotlib, Lewinsohn,

Seeley, Rohde,

& Redner,

1993)

and

lifetime prevalence estimates of experiencing a depressive
episode ranging between 8 to 18%

(Karno et al.,

1987) . While

depressive episodes tend to spontaneously remit over time
(Hollon,

Stewart,

Markowitz, 2002),

& Strunk,

2006; Hollon, Thase,

&

those suffering a single major depressive

episode are at a substantial increased risk of experiencing
additional episodes
Solomon et al.,

(APA,

2000a; Mueller et al.,

1999;

1997) . Significant variability exists in the

number of major depressive episodes experienced by those
with this disorder, but it is well established that the
number of prior depressive episodes is predictive of the
probability of experiencing additional episodes.

Indeed, the

probability of experiencing a subsequent major depressive
episode increases from 60% for those suffering a single
episode, to 70% for a second, to 90% for a third episode
(APA,

2000a).
In addition to the reduced functioning and quality of

life of the sufferer of depression (Hays, Wells, Sherbourne,

1

2
Rogers,

& Spritzer,

1995; Hirschfeld et al.,

2000), profound

negative effects are associated with the disorder including
elevated suicide risks

1988),

(Hirschfeld & Davidson

significant health risks

(e.g., myocardial infarction)

and

high economic costs. Indeed, the economic burden resulting
from reduced productivity,

sick leaves, and early death

dwarfs the actual costs of directly treating depression
(Greenberg,

Stiglin, Finkelstein,

Nevertheless,

& Berndt,

1993) .

evidence repeatedly indicates that the vast

majority of those suffering from depression receive no
specific form of treatment, or if they do receive care it
tends to be inadequate
Ormel,

(Katon, Von Korff

Lin, Bush,

1992; Narrow, Regier, Rae, Manderscheid,

1993 ; Wells, Katon, Rogers,

& Camp,

&

& Locke

1994) .

A typical Major Depressive Episode has been conceptualized
in terms of its longitudinal course and the treatment
utilized during its presence. Over a period of time the
number and severity of depressive symptoms may increase
either gradually or suddenly until criteria for a Major
Depressive Episode are met. Treatment may also commence when
one or a few symptoms become severe enough to warrant it.
Acute treatment is aimed at treating the depressive
episode in a manner that decreases the number and severity
of these depressive symptoms

(Hollon, Thase,

& Markowitz,

3
2002). This acute treatment phase in studies is
conceptualized as occurring between the time in which
treatment is first implemented to the point where depressive
symptoms lessen to a satisfactory level defined by the study
investigators. Treatment response, a clear goal of acute
treatment

is the substantial lessening of symptom severity

to a point where criteria for the disorder are no longer
satisfied,

commonly operationalized by researchers as a 50%

reduction in severity (Frank et al.,

1991) . As symptom

reduction continues past the response level,

remission may

be achieved, which is defined as the reduction in the number
and severity of depressive symptoms to a degree that is
indistinguishable from the normal population. Following
reduction of depressive symptom severity or even attainment
of remission,

the individual may experience a relapse,

in

which depressive symptoms of the same acutely treated
episode return

(Frank et al.,

1991). Relapse is especially

likely to occur if treatment is prematurely removed prior to
complete resolution of the current depressive episode
(Hollon et al.,

2002).

To reduce risk of relapse,

continuation treatment is

recommended, especially for antidepressant therapy, which
simply involves ongoing treatment beyond remission of
depressive symptoms

(Prien & Kupfer,

1986) . Although
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considerable debate continues over how long the depressive
episode typically continues, and hence how long continuation
treatment should last,

researchers typically recommended a

minimum of 6 months continued antidepressant treatment
following remission (Agency for Health Care Policy Research,
1993 ; Depression Guideline Panel,

2000; Geddes et al. , 2003 ;

Prien & Kupfer,

the dose prescribed during

1986) . Typically,

this phase is the same as taken during the acute phase.
Qualitatively indistinguishable from remission
recovery involves the resolution of the initial depressive
episode due to either successful treatment or simply the
natural course of the episode
2002). Similar to relapse,

(Hollon, Thase,

& Markowitz,

recurrence involves the return of

depressive symptoms. However, while the returning symptoms
in relapse are those of the same depressive episode, the
symptomatic return involved in recurrence derives from an
altogether new episode after recovery has been achieved
(Frank et al.,

1991) . Typically relapse and recurrence are

subjectively defined by simply how much time has passed
since the experience or observation of depressive symptoms
(i.e.,

remission).

depressive episode,

In order to prevent recurrence of another
maintenance treatment is often employed,

which involves the continued treatment of the episode after
recovery has been achieved (Frank & Thase,

1999; Kupfer,

5
1991; Prien & Kocsis,

1995; Thase,

1993) . For those whom

maintenance treatment is recommended, the same treatment
that was effectively used during the acute and continuation
treatment phases should not be changed, nor should the dose
(APA,

2000b; Franchini,

1999; Frank et al.,

Zanardi, Gasperini,

& Smeraldi

1993) . Although these models of the

course of depression and corresponding treatment phases are
largely accepted by the research community, not all research
has supported such clear distinctions among phases.

In their

review of randomized trials of continuation
psychopharmacologic treatments, Geddes et al.

(2003)

failed

to find evidence of a difference between continuation and
maintenance treatment phases as patients switched to placebo
after receiving 1-2 or 4-6 months antidepressant treatment
evidenced similar relapse rates, despite the expectation
that the patients being treated for the longer duration (4-6
months) would evidence lower relapse rates.
While the aforementioned course of depression and
treatment phases represent a relatively subjective view of
the depressive episode,

this formulation is important in

planning treatment. Acute treatment is typically straight
forward as the chief aim is to simply reduce symptom
severity. However, once the patient responds to treatment
and eventually reaches the point of remission,

important
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treatment decisions must be made. As discussed above
premature withdrawal of treatment places the patient at
considerable risk for relapse,
symptoms are present
Thase,

especially when residual

(Keller, Lavori, Kane,

1992;

1992). On the other hand, continuation treatment

certainly reduces the risk of relapse
Thase,

et al.,

(Prien & Kupfer,

1986;

1993), but at the potential cost of increased or

continued financial burden of treatment,

side effects, and

so on. Continuation treatment is most effective when
sustained well beyond the point of remission as research
indicates that the months following remission mark a
particularly vulnerable time for the patient to experience a
relapse

(Hollon, Thase,

treatment,

& Markowitz, 2002). As such,

especially pharmacotherapy,

is recommended to

continue at least 6 months following remission in order to
attain recovery (Depression Guideline Panel,
Kupfer,

2000; Prien &

1986) . This recommendation is provided given

evidence suggesting that patients are approximately three
times less likely to experience recurrence following
recovery (i.e.,

resolution of the depressive episode)

relapse following remission (i.e.,
depressive symptoms)

significant decrease in

. For those patients who experience

recurrent depression (e.g.,
episodes),

than

three or more depressive

continuing maintenance treatment is recommended
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in order to reduce the risk of experiencing recurrence
following recovery (APA,
1993). Thus,

2000b; Prien & Kocsis,

1995; Thase,

the conceptualization of the depressive episode

and treatment in terms of phases has provided a practical
benefit. However,

if a treatment was demonstrated to have

enduring effects,

this might decrease the need for long-term

or maintenance treatment.
Hollon,

Stewart,

and Strunk

(2006) present a typology

of efficacious treatments based upon both the mechanism of
action of the intervention and characteristics of the
disorder being treated. The first category of treatments,
palliative interventions,

simply suppress the manifestation

of symptoms without altering the underlying mechanisms
contributing to the expression of the disorder. As such, the
efficacy of palliative treatments remain only while the
intervention is being actively applied.

In contrast,

curative treatments manage the symptoms by addressing the
underlying mechanisms giving rise to the disorder, and thus
have an enduring effect by preventing the current episode
from returning (i.e., relapse prevention). Finally,
prophylactic interventions address underlying mechanisms
that play a role in the development of future episodes.
Consequently, prophylactic treatments also have an enduring

8
effect, but interventions in this category prevent also
prevent recurrence

(i.e.,

altogether new episodes).

Pharmacotherapy
Potentially the most exhaustively studied interventions
for the treatment of depression are pharmacotherapy and
cognitive therapy. Medications are the most researched and
utilized form of treatment for depression in the United
States

(Narrow et al.,

1993), with a multitude of well-

controlled studies demonstrating their efficacy for treating
all severity levels
Frank, Karp

Sc Rush,

(Depression Guideline Panel,
1993 ;

1993;

for review see Lieberman et al. ,

2005). Particularly extensively studied are two classes of
antidepressants,
(SSRIs)

selective serotonin reuptake inhibitors

and Tricyclic antidepressants

(TCAs), however due to

the development of safer and equally efficacious
medications, TCAs have experienced a substantial decrease
over the past three decades, while SSRIs are currently the
most utilized (Stafford, MacDonald,
the name implies,

& Finkelstein,

2001). As

SSRIs function by selectively blocking the

reuptake of serotonin,

thus prolonging the effect of

serotonin on the postsynaptic neuron (Rivas-Vazquez & Blais,
1997). TCAs affect the nervous system by either
predominantly blocking the reuptake of norepinephrine or

9
blocking the reuptake of both norepinephrine and serotonin,
as well as a variety of other neurotransmitters,

thereby

potentiating their effect by prolonging their presence in
the synapse
& Blais,

(Hollon, Thase,

& Markowitz,

2002; Rivas-Vazquez

1997). Nevertheless, the specific means by which

these actions are accomplished differ among the drugs within
each class. Despite being extensively studied, the specific
mechanisms giving rise to the effectiveness of these two
classes of antidepressants in treating major depression
remain largely elusive

(Delgado,

2004).

Approximately 30% to 50% of all patients treated with
pharmacotherapy will respond to the antidepressant
medication initially prescribed (Depression Guideline Panel,
1993 ; Hollon, Thase, Markowitz,

2002 ; Mulrow et al. ,

1999)

and about 50% of those failing to respond to the original
medication will successfully respond to an alternative
medication

(Thase Sc Rush,

1997) . Although numerous

antidepressants are available and new pharmacological
treatments are continually being developed, reviews of the
research suggest that no single antidepressant demonstrates
a clear advantage in efficacy over the others
Depression Guideline Panel,
equality in efficacy,

(APA, 2000b;

1993) . Despite this apparent

the classes of antidepressants do

substantially differ along multiple dimensions that have
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driven the medical community to favor certain classes over
others. Most notable of these differences concerns the
dangerousness of the drug. For example, MAOIs have witnessed
a considerable decrease in use since the 1960s owed largely
to their interactions with everyday foods, namely cheeses
(i.e., the cheese effect),

that result in life-threatening

consequences. An additional factor that has shaped
prescription trends includes the side effects and risk of
.

death in overdose with the use of certain classes. TCAs are
especially notable in this category, as approximately 30% of
patients taking drugs from this class experience side
effects that ultimately contribute to their decision
terminate use

(Depression Guideline Panel,

1993). As a

result of such concerns with lethality and unwanted side
effects

a large majority of psychiatrists and physicians in

the United States prescribe selective serotonin reuptake
inhibitors

(SSRIs)

as their first choice in treating

depression (Olfson et al., 2002). In addition to their
decreased side effect profile are advantages in safety from
overdose and simplified use
Vazquez & Blais,

(Thase & Kupfer,

1997). Nevertheless,

their own side effects and cautions
Brambilla, Cipriani, Hotopf,
Laurencic,

& Malone,

2006) .

1996; Rivas-

SSRIs are not without

(for reviews,

& Barbui,

see

2005; Khawam,
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Despite the wel1-documented efficacy of antidepressants
in treating depression,

the efficacy of antidepressants in

preventing the reoccurrence of depressive symptoms appears
to continue only as long as pharmacological treatment is
continued (Hollon,

Thase, Markowitz

2002), and thus, can be

classified as a palliative intervention (Hollon, Stewart,
Strunk,

2006).

Indeed,

&

evidence from numerous quantitative

reviews suggest that continuation of antidepressant
treatment decreases the relative risk of relapse by
approximately half,

such that the risk of relapse decreases

from between 41% and 50% to 19% and 22% for patients
continuing pharmacotherapy (e.g., Geddes et al., 2003; Prien
Sc Kupfer,

1986) . Conversely,

lasting protective effects

evidence indicating any long-

(i.e.,

curative or prophylactic)

of antidepressant treatment following discontinuation is
lacking, thereby suggesting that the antidepressants only
serve to suppress the expression of depressive symptoms
(Hollon et al.,

2006) . Therefore, upon removal of the

antidepressant effect
adherence)

(i.e., treatment discontinuation, non

relapse and recurrence are more likely to occur.

Based upon such findings,

coupled with the

abovementioned evidence of the recurrent nature of
depression,

it is recommended that antidepressant treatment

extend up to nine months beyond remission of the acute
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episode in attempt to establish full remittance
Anderson, Nutt,

& Deakin,

Guideline Panel,
guidelines,

2000; APA

(e.g.,

2000b; Depression

1993; Paykel & Priest,

1992). Despite such

substantial differences in the

psychopharmacological management of depression exist, which
may result in patients receiving less than optimal care
(Hirschfeld et al.,

1997).

Compounding this problem numerous studies indicate that
early discontinuation and non-adherence of antidepressants
across multiple clinical contexts are common (e.g., Dunn,
Donoghue, Ozminkowski,

Stephenson,

Katzelnick, Kobak, Jefferson,
Olfson, Druss,

& Pincus,

Von Korff, Rutter,

& Hylan,

& Greist,

1996; Lewis, Marcus

2004; Melfi et al.,

& Petterson,

1999;

1998; Simon,

2001) . For example, a recent

survey found that 42.4% of patients stop taking their
antidepressant medications during the first 30 days, while
only 27.6% successfully continue pharmacotherapy beyond 90
days

(Olfson, Marcus, Tedeschi,

& Wan,

2006) . Although

unwanted side effects of the prescribed antidepressants are
the most typical reason for discontinuation, additional
explanations include insufficient patient education, patient
ambivalence about mental health or taking a psychotropic
medication

(Hollon, Thase,

& Markowitz,

2002),

low

socioeconomic status and education, and ethnicity (Olfson et
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al., 2006). A particularly notable protective factor
associated with improved treatment continuation adherence
was participation in psychotherapy.
There is virtually universal agreement of recommending
continued antidepressant treatment for a minimum of four to
six months following recovery from the depressive episode
(e.g., APA,

2000b). Regardless,

a vast majority of research

trials investigating the efficacy of pharmacotherapy fail to
adhere to these guidelines,

instead discontinuing treatment

prematurely. Combining data from both research implementing
brief and prolonged pharmacotherapy trials suggest that the
effect of antidepressant interventions are largely
prophylactic

(Hollon, Stewart,

& Strunk,

2006). Despite the

clearly documented efficacy of pharmacotherapy, this
treatment for depression evidences significant limitations.
Antidepressants appear to offer largely prophylactic
benefits, necessitating long-term antidepressant treatment
to prevent return of the depressive symptoms, not to mention
the potential indefinite antidepressant treatment for those
at high risk for relapse and recurrence. Further,

there is

only a 50% probability of responding to the first prescribed
medication, which given the many potential side-effects
raises concerns. Research also finds substantial non
adherence practices and premature discontinuation behaviors
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of patients using antidepressant medications. Given these
limitations of pharmacotherapy in the treatment of
depression the potential curative and prophylactic effects
of cognitive behavior therapies suggested in the literature
are profound and warrant close attention (Hollon, Stewart,
Strunk,

&

2006).

Cognitive Behavioral Therapy
Cognitive therapy (CT; Beck,

1967), or collectively

referred to as cognitive-behavioral therapy (CBT)

is likely

the most well established psychotherapeutic treatment for
depression (Hollon, Thase,
trials

2005)

Butler, Chapman, Forman,

and meta-analyses

& Beck,

Gloaguen, Cottraux,

Cucherat,

Berman,

1990)

& Neimeyer,

2002) .

Bishop, Glen, Whalley,

(e.g., Blackburn

1981; DeRubeis et al.,

& Markowitz,

2006; Dobson,

& Blackburn,

In controlled
& Christie,
(e.g.,
1989;

1998; Robinson,

CBT has been repeatedly

demonstrated to be equally effective or even superior to
pharmacotherapy (e.g., Dobson,

1989; Robinson et al. ,

1990)

in treating the acute phase of adult depression (e.g.,
palliative intervention). Moreover, mounting evidence
suggests that CBT may have an enduring effect,

reducing the

risk of relapse following successful treatment of depression
(e.g., Blackburn, Eunson,

& Bishop,

1986; Evans et al.,

15
1992; Hollon et al.,

2005; Kovacs, Rush, Beck,

1981; Simons, Murphy

Levine,

preventing recurrence

(Fava, Rafanelli, Grandi,

Belluardo,

& Wetzel,

1986),

& Hollon,
as well as
Conti,

&

1998) .

One notable exception is the National Institute of
Mental Health Treatment of Depression Collaborative Research
Program (TDCRP; e.g.

Shea et al.,

1992), which is the only

study failing to demonstrate an enduring effect following
CBT discontinuation, even showing that CBT was less
effective than medications in acute treatment, but some
authors have pointed to differential outcomes from the sites
in which CBT was implemented (Jacobson & Hollon,

1996).

These authors note that examination of the data and study
methodology suggests that the site with the most experienced
CBT therapists demonstrated the best outcomes from CBT. Even
so, TDCRP represents only one study, albeit a large and
methodologically rigorous study, that has failed to
demonstrate equal or superior effects of CBT over
medications among numerous other research endeavors
supporting the palliative,

curative, and potentially

prophylactic effects of CBT.
The cognitive model holds that perception of an event
substantially influences the individual's reactions,
including emotional, behavioral, and physiological,

to that
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event

(Beck,

1969; Beck, Rush, Shaw,

such,

CBT seeks to identify,

& Emery,

1979). As

challenge, and change

dysfunctional thoughts and beliefs that are viewed as
underlying the development of depression. These goals are
accomplished through various processes. The therapist trains
the patient to develop skills in methodically collecting
environmental data to combat biased and dysfunctional
information processing styles and beliefs
1979). Testing these new and old (i.e.

(Beck et al.,

maladaptive)

perceptions, patients perform behavioral experiments to
provide actual data to support or disconfirm these
perceptions. Simultaneously, patients are trained to engage
in cognitive restructuring techniques that function to
realistically evaluate the legitimacy of their thoughts and
beliefs, and thus, develop new and more adaptive beliefs and
information processing strategies. Fundamental to CBT is the
endeavor to train the patient to become his or her own
therapist by teaching them to independently apply and engage
in these thought modifying skills and techniques, providing
the patient with the abilities necessary to respond to
dysfunctional thinking in the future

(J. S. Beck,

1995).

In an attempt to explain the implicated curative and
prophylactic effects of CBT, numerous studies have examined
the potential mechanisms underlying the enduring influences
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of CBT. Given the foundational theory of CBT arguing that
improvement follows modifications of maladaptive information
processing strategies and beliefs
1979),

(Beck,

1991; Beck et al.,

it is reasonable to examine whether such changes are

associated with immediate and long-term outcomes.
research has supported this theory. However,

In fact

research has

also demonstrated that patients treated with antidepressants
also exhibit improvements in maladaptive automatic thoughts
(e.g.,

Imber et al.,

1984). Thus,

1990; Simons, Garfield

& Murphy,

it appears that these cognitions improve as

mood elevates, and may better represent a symptom of
depression rather than a cause

(e.g., Hamilton & Abramson,

1983; Lewinsohn, Steinmetz, Larson,
Persons Sc Rao,

& Franklin,

1985; Simons, Garfield,

1981;

& Murphy,

1984) .

Nevertheless, CBT may produce unique cognitive changes in
underlying beliefs
processing styles

(e.g., core beliefs)
(e.g., attributions)

depressed individuals

(Hollon,

Stewart,

and information
that are common to
Sc Strunk,

2006) .

These underlying beliefs and processing tendencies may
act as latent schemas that become activated during a
negative mood state or event
et al . ,

1992 ; Ingram,

Sc Miranda,

(diathesis-stress model; Hollon

1984 ; Miranda Sc Persons

1992 ; Riskind Sc Rholes,

1994; Teasdale,

1983,

1988).

1988; Persons

1984 ; Segal Sc Ingram,

In a study supporting this
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hypothesis, Hollon, Evans,

& DeRubeis

(1990)

found that

patients successfully treated with CBT exhibited superior
improvements in attributional styles and that this
difference predicted the elevated relapse rate observed in
patients treated to remission with antidepressants. Although
limited,

this study, along with additional research (e.g.

Seligman, Schulman,

& DeRubeis,

1999), provides evidence

supporting the hypothesis that changes in underlying
cognitive processes
styles)

(e.g., beliefs,

information processing

are responsible for the prophylactic effects

observed in patients participating in CBT.
Evidence repeatedly indicates that the vast majority of
those suffering from depression receive either an
unspecified treatment or inadequate care
1997; Katon, Von Korff, Lin, Bush,
Regier, Rae, Manderscheid,
Rogers,

& Camp,

& Locke,

(Hirschfeld et al.,

& Ormel,

1992; Narrow

1993; Wells, Katon

1994) . Surprisingly, while treatment of

depression has increased over the recent decades, most
notably with prescription of antidepressant medications,
depression continues to be inadequately treated (Olfson et
al . ,

2002) . Multiple factors are involved in this poor

performance,

including missed diagnoses

(Hirschfeld et al.,

1997), comorbidity (Enns, Swenson, McIntyre, Swinson,
Kennedy,

2001; Hirschfeld et al., 2003),

inadequate

&
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intervention,
et al.

insufficient treatment intensity (Hirschfeld

1997; Nutting et al., 2002),

remission (Ballenger,

failure to treat until

1999; McIntyre & O'Donovan, 2004),

societal stigma, and lack of knowledge of the possible
benefits of treatment
al.,

(Hirschfeld et al.,

1988; Wells et al.,

1994). This lack of treatment

results in substantial "human cost"
2004

p.

IIS),

1997; Regier et

(McIntyre & O'Donovan,

including medical, psychiatric,

and economic burden (Antonuccio, Thomas
McIntyre Sc O'Donovan,

functional

& Danton,

1997;

2004) . Conversely, adequate treatment

of depression decreases lost economic productivity and
utilization of health care
1992 ; Sclar et al. ,

(Mintz, Mintz, Arruda,

1994 ; Von Korff, Ormel, Katon,

Sc Hwang,
Sc Lin,

1992). Indeed, the economic burden resulting from reduced
productivity,

sick leaves, and early death far outweighs the

actual costs of directly treating depression (Greenberg,
Stiglin,

Finkelstein,

Sc Berndt,

1993) .

The common occurrence and substantial cost of
depression has encouraged the development of efficacious
treatments. Although these interventions have been shown to
be adequate palliative interventions
Thase,

Sc Markowitz

(for review see Hollon,

2002), they have been less adequate in

preventing relapse and recurrence
prophylactic). However,

(i.e., curative or

evidence of CBT's equitable or even
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superior effect in treating depression compared to
antidepressants combined with research supporting CBT's
potential protective effects suggests that CBT may offer the
patient and society substantial savings
Strunk,

2006; Hollon, Thase

(Hollon, Stewart,

Sc Markowitz,

&

2002) . Indeed,

despite the general perception of antidepressant treatment
being more cost-effective than psychotherapy, a growing body
of research is suggesting that CBT is cheaper than
pharmacotherapy (e.g., Antonuccio, Thomas,
Scott,

Palmer,

Corry, Haby,

Paykel, Teasdale,

Carter,

initially cheaper

& Andrews,

& Danton

& Hayhurst,

19 9 7 ;

2003; Vos,

2005). Pharmacotherapy is

(Scott & Freeman,

1992; Gabbard et al.

1997). However, given the cost of maintenance
antidepressants the cost offset of time-limited CBT could be
substantial

(Hollon et al.). An additional benefit is the

avoidance of potential side-effects of the medications
(Antonuccio et al.,

1997). Particularly notable, given the

potential curative and prophylactic qualities of CBT,

such

cost benefits could extend over many years. Besides the
potential economic benefits,

effectively treating depression

and decreasing relapse and recurrence offers profound "human
savings" in terms of personal suffering,

strained

relationships with significant others, and risk of suicide
(McIntyre & O'Donovan, 2004) . Based upon these potential

21
superior psychiatric, medical, and functional benefits of
CBT when compared to pharmacotherapy,

some have argued that

CBT be the first-line of treatment for depression (e.g.,
Antonuccio et al.,

1997).

Despite evidence suggesting CBT's superior efficacy
over pharmacotherapy in reducing relapse following treatment
discontinuation,

review and meta-analytic studies comparing

the two interventions have only investigated those studies
allowing a direct comparison of CBT and pharmacotherapy. As
such,

considerable follow-up research providing important

information concerning the enduring effects of these
treatments has been ignored, particularly those studies
investigating CBT and pharmacotherapy in isolation.
Responding to the paucity of studies that directly compare
the relapse rates of both interventions, the current study
incorporates studies which have performed a treatment trial
of one of the treatments in isolation. The purpose of the
current meta-analysis is to combine and analyze follow-up
data of relapse rates after acute phase treatment of either
CBT or pharmacotherapy in order to provide a better
understanding of any similarities or differences that may
exist between the two treatments in terms of enduring
effects.

Methods

Selection Requirements
Studies included in the meta-analysis were required to
meet several inclusionary criteria. The first stage of
identifying studies to include in the meta-analysis involved
the following criteria:
1)

Scientific articles

(e.g., dissertation abstracts

excluded);
2)

English language;

3)

human participants;

4)

adult participants

(studies specifically targeting

children, adolescents, or older adults were excluded);
5)

community sample

(studies targeting special populations

[e.g., cancer sufferers]
6)

were excluded);

treatment on an outpatient basis

(studies of inpatient

populations were excluded);
7)

participation in acute phase treatment must be

randomized;
8)

treatment must include individual cognitive therapy, or

individual cognitive-behavior therapy, or pharmacotherapy in
the form of tricyclic antidepressants
serotonin reuptake inhibitors

(SSRIs);

22

(TCAs)

or selective
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9)

studies including multiple treatment groups with at

least one group receiving one of these treatments were
included (studies including participants receiving
combination treatment including one of the acceptable
treatments were excluded [e.g., both CBT and
pharmacotherapy]);
10)

full CBT must have been implemented (studies applying

specific components of CBT were excluded);
11)

participants receiving acute phase treatment must have

met criteria for major depression as determined by a set
criteria defined by the researchers
Research Diagnostic Criteria
Robins,
12)

(e.g., DSM diagnosis,

[RDC; Spitzer, Endicott,

1979], Beck Depression Inventory [BDI]

&

cut-off);

studies including participants meeting criteria for

other psychiatric disorders, particularly dysthymia, bipolar
disorder, or minor depression, were excluded;
13)

acute phase treatment must have focused on the

treatment of major depression;
14)

follow-up relapse data must have been available

exclusively for participants responding to acute phase
treatment as defined by the researchers

(e.g., no longer

meeting DSM criteria for a major depressive episode or BDI
cut-off score);
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15)

follow-up data indicating relapse rates must have been

available for a minimum of 6-months post-treatment. The
final stage of evaluating the study for inclusion involved
ensuring adequate reporting of data in a manner that allowed
researchers to calculate relapse rates relative to time
period post-treatment.

Literature Search
A computerized literature search was performed using
both PsycINFO (1960-2007)

and PubMed (1960-2007) . Entered

search criteria included "cognitive therapy AND depression
AND follow-up," "pharmacotherapy AND depression AND follow
up," and "antidepressant AND depression AND follow-up." This
search of PsychINFO and PubMed yielded 1,060 and 3,136
items,

respectively. However, the vast majority of these

results were inappropriate for the current analysis as they
did not address long-term outcome in participants with
depression following treatment with CBT or antidepressants.
Only those studies meeting the inclusionary criteria
presented below were retained. The bibliographies of these
studies were also reviewed for potential inclusion in the
current study.

25
Correcting For Dropout
Inherent to longitudinal studies is the problem of
dropouts or losses to follow-up. This difficulty is
particularly notable for the current investigation, as it
examines the proportion relapse at multiple time points.
Such an examination would be easy if the sample sizes
remained constant across follow-up periods. However,

sample

sizes in follow-up commonly decrease, making it difficult to
compare cumulative relapse rates across follow-up times.
To illustrate,

imagine that a sample of 100 participants had

a relapse rate of 50% at Time 1,
remission. Now,
participants,

leaving 50 participants in

let's say of these remaining 50

10 are lost to follow-up at Time 2,

participants. Of these 40, 20 participants

(50%)

leaving 40
relapse,

leaving 20 of our original sample in remission. Certainly we
can conclude that between Time 0 and Time 1 50% of the
sample relapsed, and likewise for the time between Time 1
and 2. However,

if we attempt to provide an overall relapse

rate for the period between Time 0 and Time 2 our current
percentages are of no use. For example,

summing our two

relapse percentages results in a 100% relapse rate, which is
clearly inaccurate given the 20 participants remaining in
remission. This complication arises due to the changes in
sample size, placing our percentages on incompatible scales
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if the purpose is to sum them to calculate cumulative
relapse rates.
To correct for this problem the relapse rate at Time N
can be converted to the scale at the first follow-up point,
where N represents the follow-up point after the first
follow-up period. This is accomplished by applying the
following equation:

Corrected RelapseT2 = Relapse^ +

[(1 - RelpaseTi) x

(RelapseT2) ]

where Corrected RelapseT2 is the proportion relapse at
follow-up periods following the initial follow-up point,
Time 1.

Thus, RelapseT! is the proportion relapse at the

initial follow-up point and RelapseT2 is the raw relapse
proportion between follow-up points N and N-l. This
procedure involves assuming that participants lost to
follow-up would have evidenced the same relapse rate as
those remaining in the study.

In the current example,

50 participants had remained in the study,

.50

if all

(25

participants) would have relapsed. This assumption allows us
to calculate the proportion relapse in terms of the
proportion relapse of the initial sample of 100 participants
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estimating the number of participants who would have
relapsed in the loss to follow-up group:

Corrected RelapseT2

= .5 +

[(1

= 50 +

[ ( .5) x (.5)]

-5) x (.5)]

= .50 + .25
= . 75

Thus, at Time N

.75 of the initial sample of 100

participants is estimated to have evidenced a relapse,
compared to .50 evidencing a relapse at Time 1. This
approach was used in the current study to estimate
cumulative relapse rates in situations when losses to
follow-up were observed across follow-up points.

Coding Relapse Criteria
A coding system was developed to classify the relapse
criteria used by studies in order to test for potential mean
group differences between treatment groups. Although no
clear consensus exists in the literature, research on the
various assessment tools utilized in the studies were used
to create a three level scheme for classifying each study's
relapse criteria: 1) weak, 2) moderate, and 3)

strict.

Research on the Hamilton Depression Rating Scale

(HDRS)
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suggests that the following scores classify the intensity of
depression with the coding scheme applied to the scores in
parentheses: scores of 0-7 indicate non-depressed
individuals
moderate

(weak),

8-17 are mild depression (weak),

18-24

(moderate), and greater that 24 are severely

depressed (strict; Endicott,

Cohen, Nee,

Fleiss,

Sarantakos,

Chelminski,

& Posternak,

1981; Zimmerman

&
2004) .

The following cutoff scores for the EDI are recommended in
the literature, again with the coding scheme in parentheses:
0-8 non-depressed (weak),

9-14 mild depression (weak),

15-30

moderate depression (moderate), and greater that 30 severe
(strict; Frank,
al . ,

Prien, Jarrett, Keller, Kupfer, Lavori, et

1991; Kendall, HoiIon, Beck, Hammen,

Montgomery-Asberg Depression Rating Scale
suggested are remission < 11
24 < Moderate < 30

(weak),

(moderate)

& Ingram,
(MADRS)

scores

11 < Mild < 24

and 31 < Severe

1987) .

(weak),

(strict;

Sugawara, Higuchi, Yoshida, Takahashi, Kamata, Naito, Sato,
& Shimizu,
S)

2006) . Clinical Global Impression- Severity (CGI-

scores are commonly classified as 1-3, not ill, minimally

ill, and mildly ill,

respectively (weak criteria),

4-5

moderately and markedly ill, respectively (moderate
criteria), and 6-7,

severely and very severely ill,

respectively (strict criteria). For Longitudinal Interval
Follow-up Evaluation (LIFE)

scores,

scores of 1-3 are
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categorized as usual self,

residual, and partial remission.

respectively (weak criteria),
definite criteria,

scores of 4-5 as marked and

respectively (moderate criteria), and a

LIFE score of 6 categorized as definite criteria,
(strict criteria; Keller, Lavori,
Endicott, McDonald-Scott,

severe

Friedman, Nielson,

& Andreasen,

1987). Formal

diagnostic systems such as the Structured Clinical Interview
for DSM-III-R (SCID; Spitzer, Williams, Gibbon

8c First,

1989) were coded as moderate, while diagnoses made based
upon clinical judgment were deemed weak. Finally,

relapse

defined as the participant returning to treatment was coded
as weak.

Effect Sizes
The current meta-analysis was based upon procedures
recommended by Hedges and Olkin (1985)

and Lipsey and Wilson

(2001) . Proportion relapse numbers were acquired from each
study and effect sizes were based upon these statistics.
Although effect sizes can be presented as proportions, the
current study utilized the logit method in performing the
statistical analyses in order to best account for variation
among studies

(Lipsey & Wilson, 2001) . The logit method

involves converting proportions to logits and performing all
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statistical analyses with the logits using the following
formulas:

ES! = loge
Wj

=

nP (1

(P /

[1

P] )

P)

where ESi is the logit effect size,
variance weight,

wi is the inverse

P is the proportion of relapsed

participants, and n is the total number of participants in
the sample

(Lipsey & Wilson,

statistical analysis,

2001) . Following the

the logit effect sizes were then

converted back into proportions using the following formula:

P = el09it /

(elogit + 1)

where el091t is the base of the natural logarithm.
approximately 2.178,

raised to the power of the logit,

namely ESj from the above calculations. The proportions,

P,

derived from calculations based upon ES! are reported and
all interpretations are based upon the proportions. The
logit method was utilized due to various statistical
advantages, namely increasing the sensitivity of differences
between effect sizes.
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Homogeneity
A homogeneity of variance analysis was performed during
each test by calculating Cochran's Q statistic

(Cochran,

1954), which tests the differences in effects and determines
whether a fixed effects or a random effects model will be
appropriate for analyzing the data. The Q statistic is then
compared to the Chi-square distribution with k

1 degrees

of freedom, where k is equal to the number of effect sizes
(Hedges & Olkin,

1985).

If the calculated Q statistic

exceeds the respective critical value of the chi-square
distribution with k

1 degrees of freedom,

the null

hypothesis of homogeneity of variance is rejected and the
alternative hypothesis of heterogeneity is supported,
indicating that the variance exceeds what would be expected
solely from sampling error

(i.e., effect sizes sampled from

different populations).
The current study hypothesized that the null hypothesis
of homogeneity of variance would be rejected,
group differences

that between-

(i.e., treatment type) would significantly

account for some or all of the excess variability between
effect size groups. As such,

the total variability was

partitioned into both the portion accounted for by treatment
type

(0B)

and the residual variability that could not be

accounted for

(Qw; e.g.,

sampling error, unknown variables) .
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If Qb is statistically significant the mean effect sizes
between the treatment groups differ above and beyond
sampling error. Likewise, a significant Qw indicates that
neither the between-group variable

(i.e.

treatment type)

nor sampling error fully account for the variability across
effect sizes, and thus,

the residual variability needs to be

accounted for in the weighting of the effect sizes. Within
this, with both significant Qw and QBl a mixed effects model
can be applied to the data. This model assumes that the
excess variability among the effect sizes above and beyond
sampling error is comprised of both systematic
treatment type)

(e.g.,

and unsystematic variance. Thus,

the mixed

model allows the analyst to account for the between-group
variance component

(treatment type), while weighting the

mean effect sizes and confidence intervals to account for
the greater uncertainty in the calculations resulting from
residual variability.

Although the mixed effects model

comes at a price of sacrificing statistical power for
identifying moderator variables,

it is less likely to

produce Type I errors because it better accounts for
between-group heterogeneity that the fixed effects model may
fail to account for when,
assumptions,

contrary to the model's

significant between-group heterogeneity exists

(Lipsey & Wilson,

2001) .
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Procedure
Proportion relapse figures were converted to logits and
effect sizes were calculated using the logits. Effect sizes
and confidence intervals based upon the logit were then
converted back to proportions and interpreted. Logit effect
sizes were calculated using the meta-analytic SPSS macro
METAF.SPS, written by Wilson (Lipsey & Wilson

2001) with

SPSS 15.0 for Windows.
After studies were coded for relapse criteria,
treatment group comparisons were performed using an oneway
analysis of variance to examine potential significant
differences in coded relapse criteria,

treatment time, and

follow-up times. These comparisons were made based upon the
hypothesized potential impact of these variables on relapse
rates, with briefer treatment, weaker relapse criteria, and
longer follow-up increasing relapse rates. Following
calculation of the logit effect sizes, unmoderated fixedeffects models of homogeneity of variance analyses were
performed to test the hypothesis of significant
heterogeneity and assess for the appropriate model to fit
the data. If this homogeneity test indicated that there was
significant heterogeneity,

the moderator variable, treatment

type, was included in the model.

If significant between-

group heterogeneity remained with the inclusion of treatment
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type,

the fixed effects model was rejected and a mixed model

was utilized to account for both the systematic and random
heterogeneity of variance.

If treatment type remained a

significant moderator, the effect sizes were converted back
to proportions and were reported along with the 95%
confidence intervals. These analyses were performed at three
time periods: 1)

collapsing across all follow-up points,

52-weeks post-treatment, and 3)

2)

104 weeks post-treatment.

Lastly, the affect of publication bias, or the "file
drawer problem," on the results reported in this meta
analysis was examined for fixed effects models using
Rosenthal's

(1979)

fail safe n statistic. The fail safe n

statistic evaluates the robustness of the results from the
meta-analysis by estimating the number of unpublished
studies with null findings, n,

required to render the

findings from a meta-analysis nonsignificant under a fixed
effects model. Although these calculations were made,

they

are not reported here due to the use of a mixed effects
model for most of the computations, which generally makes
the fail safe n of little importance due to the already
conservative approach of this model

(e.g., Rosenberg,

2005) .

Results

Tables 1 and 2 provide a description of the ADT and CBT
studies,

respectively,

included in the meta-analysis. A

total of 23 articles met our inclusion criteria, with 19
articles for ADT and 10 for CBT treatment conditions, and
having 6 articles examining both treatment conditions. These
articles provided 26 follow-up points for ADT and 19 for
CBT, with an average follow-up time of 85 and 73 weeks,
respectively. One-way analyses of variance

(2x3)

across

all studies failed to yield any significant group
differences for follow-up time
. 524)

(F = .413,

treatment duration (F = 1.223

and relapse criteria (F = .635,
Effect sizes,

df = 44, P =

df = 35, p = .276)

df = 44, P =

.430) .

reported as weighted mean proportions,

and 95% confidence intervals for ADT and CBT treatment
groups for the entire follow-up period,

52 weeks, and 104

weeks are presented in Table 3. See Figure 1 for box and
whisker plots contrasting weighted proportion relapses as a
function of follow-up time and treatment group.

Initially

applying a fixed model to the entire follow-up sample
yielded a significant effect for treatment group. However,
significant heterogeneity was found using the fixed effects
model,

Qtotai(44)

= 140.41, p < .0001. Computing the analog
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Table 1

Characteristics of APT studies included in the meta-analysis
Relapse
Criteria*

Tx
Duration
(weeks)

FollowUp
(weeks)

N

Proportion
Relapse

Blackburn et
al. (1986)

1

20

104

9

. 78

Evans et al.
(1992)

2

12

35
52
70
87
104

10

. 50
.5
. 50

Study

. 50
. 50

Fava et al.
(1994)

2

13-22

104

20

.35

Fava et al.
(1996)

2

13-22

209

20

. 70

Fava,
Rafenelli,
Grand!,
Canestri et al.
(1998)

2

13-22

313

20

. 75

Fava,
Rafenelli,
Grandi, Conti
et al. (1998)

2

13-22

104

20

.80

Fava, Ruini et
al. (2004)

2

13-22

313

20

. 90

Gilaberte et
al. (2001)

3

32

48

28

.40

Hollon et al.
(2005)

3

16

52
104

35
6

. 76
. 84

Kovacs et al.
(1981)

2

12

52

17

. 82
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Montgomery et
al . (1988)

2

Montgomery &
Dunbar (1993)

1

8

Montgomery,
Rasmussen et
al . (1993)

2

Rapaport et al.
(2004)

94

.37
.46
. 58

52

67

. 43

6

24

42

. 55

2

8

36

93

.40

Robert et al.
(1995)

1

8

24

74

. 24

Schmidt et al.
(2000)

3

13

25

122

. 47

Shea et al.
(1992)

2

16

78

18

. 61

Simons et al.
(1986)

2

12

52

9

. 67

Terra et al.
(1998)

1

24

52

94

.35

* 1 = weak,

26

26

39
52

2 = moderate,

& 3 = strict

to the ANOVA revealed that treatment group accounted for
significant portion of the between group variability using
the fixed effects model /

Qbet ween

(1)

= 17.80,

P <

.0001.

Despite inclusion of treatment type as a moderator,
significant heterogeneity remained in the model,
122.61, P <

0within(43)

.0001. As a result of the statistically

significant residual heterogeneity, the fixed effects model
was rejected and a mixed model was applied to the data.

=

Table 2
Characteristics of CBT studies included in the meta-analysis

Study

Relapse
Criteria*

Tx
Duration
(weeks)

Follow-Up
(weeks)

N

Proportion
Relapse

1

20

104

13

0.23

2

12

35
52

10

0.1
0.1
0.1
0.1
0.2

27

0.11
0.19
0.48
0.48

52

35

0.43

104

20

0.57

Blackburn et
al. (1986)

Evans et al.
(1992)

70
87
104
Gortner et
al. (1998)

3

12-20
sessions

26
52
78
104

Hollon et
al. (2005)

3

16

Jarrett et
al. (2001)

3

12-14

104

25

0.49

Kovacs et
al. (1981)

2

12

52

18

0.56

Quiring et
al. (2002)

1

16

52

41

0.24

Shea et al.
(1992)

2

16

78

22

0.41

Simons et
al . (1986)

2

12

78

10

0.2

Thase et al.
(1992)

1

16

52

50

0.32

* 1 = weak,

104

2 = moderate,

& 3 = strict

0.29
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Table 3
Comparison of weighted mean proportion relapse between CBT and ADT for
three follow-up periods.

Follow-up
period
(weeks)

n

Weighted Mean
proportion
relapse

95% Cl

z

P

(df)

26

. 53

(.47;
.60)

. 97

.33

19

.32

( .25;
.40)

16.36***
(1)

.4.37

7

. 57

( .44;
.69)

1.02

6

.32

(.20;
.45)

.2.59

5

. 63

( .44;
. 78)

1.34

. 18

6

.39

(.26;
. 54)

-1.47

. 14

Qbe tween

All
ADT
CBT

<

.001

52
ADT
CBT

6.83**
(1)

.31
<

.01

104
ADT
CBT

3.85*
(1)

All data presented based upon mixed effects
models
* p < . 05 . ★ 'k P < . 01 . •k k k P < . 001

Significant heterogeneity emerged with the mixed effects
model,

Qtotai(44)

= 68.06,

p =

.0115.

The analog to the ANOVA

revealed statistically significant between group
variability,

0bet ween (1)

= 16.36, p = .0001. The weighted

effect size, converted into a proportion (P),

for the CBT

treatment group across all follow-up points was significant,
P =

.32,

95% confidence interval

(Cl)

=

(.25,

.40),

z =

40
4.35, p <
95% Cl =

.0001. ADT failed to reach significance,
( . 47,

.60) ,

z = -.24,

P =

P = .53,

. 81 .
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Figure 1. Box-and-whisker plot contrasting weighted
proportion relapses as a function of time of follow-up and
treatment group.

A fixed effects model was applied to relapse data at 52
weeks follow-up, producing a statistically significant
effect for treatment type. Like above however, the fixed
effects model revealed significant variability, Qtotai(12)
52.03, p < .0001. The analog to the ANOVA for the fixed

=
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effects model indicated significant between group
heterogeneity,

Qbet ween (1)

= 13.62, p < .001. Even after

inclusion of treatment type in the model,
residual variance remained,

significant

Qwithin(H) = 38.41, P =

.0001,

and thus the fixed effects model was again rejected.
Applying a mixed effects model, non-significant variance
emerged,

Qtotai(12)

= 18.86, p = .09. However,

the analog to

the ANOVA revealed significant between group variance,
Qbet ween

(1)

= 6.83, P <

.01, but non-significant residual

variance. A significant proportion effect size for CBT
treatment at 52 weeks was found,
.45)

z = -2.59, P <

significance,

P = .32,

95% Cl =

( .20,

.01. ADT did not achieve statistical

P = .57,

95% Cl =

(.44,

.69),

z = 1.02, P =

. 31.
Relapse at 104 weeks follow-up was examined using a
fixed effects model, which yielded significant
heterogeneity,

Qtotai(lO)

= 25.07, p = .005. Performing the

analog to the ANOVA revealed both significant between group
heterogeneity,

Qbet ween (1)

heterogeneity,

Qwithin(9)

= 5.49, P = .02, and within group
= 19.58, P = .02. Rejecting the

fixed effects model due to statistically significant
heterogeneity, a mixed model was applied to the data
producing non-significant variance Qtotai(lO)

= 13.08, p =

.22. The analog to the ANOVA revealed significant between
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group heterogeneity,

Qbet ween (1)

variance was non-significant,

= 3.85, P <
Qwithin(9)

.05. Residual

= 9.23, p = .42.

Effect sizes did not reach significance at 104 weeks for
CBT,

P =

.39,

95% Cl =

( .26,

. 54) ,

z = -1.47, p = .14

ADT

P =

.63

95% Cl =

(.44,

.78),

z = 1.34, p = .18.

or

Figure 2 shows the scatterplot of proportion relapse for
each CBT and ADT studies at each follow-up point reported
between weeks 24 and 104. Transposed on the scatterplot are
best fit quadratic regression lines and 95% Cl for each
treatment group. A qualitative analysis of the graph reveals
a general trend favoring CBT as producing decreased relapse
for participants with depression treated to early remission.
As can be seen in Figure 4, the quadratic best fit line
suggests that relapse rates are greatest closest to the time
of treatment discontinuation, with the relapse rate
decreasing the longer the duration of time from the initial
treatment termination.

Particularly interesting, the fit

line for ADT evidences an elevated rate of relapse between
approximately 24 and 70 weeks post-treatment compared to
CBT. However,

following this period, the relapse rate for

individuals treated with pharmacotherapy sharply decrease,
while the CBT group levels at an even rate.
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Discussion

The current meta-analysis represents a broader
examination of the evidence for enduring effects of
treatment for depression. This study found that CBT had
greater protective effects following treatment termination
than did pharmacotherapy. Specifically, the hypothesis was
supported that CBT-treated individuals would evidence lower
risk for subsequent return of depression compared to
antidepressant-treated individuals. The present meta
analysis revealed an overall decline in relapse risk 24 to
313 weeks following treatment termination for individuals
treated with CBT. However,

further analysis of the data

revealed that this protective effect was not significant at
104 weeks follow-up as CBT and ADT revealed no differential
impacts on relapse proportion at this time point. Given the
diversity of the studies included in the current meta
analysis,

it was not surprising to find statistically

significant heterogeneity that could not fully be accounted
for by treatment type as a moderator. Nevertheless, the
residual variance was accounted for through the
implementation of a mixed effects model.
The present meta-analysis provides further support for
earlier reviews

(e.g., Antonuccio, Danton,
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& DeNelsky,

1995;

45
Gloaguen et al.

1998; Hensley, Nadiga,

& Uhlenhuth,

2004)

suggesting the protective role of CBT in relapse of
depression. Notably, the current meta-analysis drew upon a
range of research that prior to this study has been ignored
in the review literature. As such,

this meta-analysis

represents a first step in attempting to quantifying the
differential enduring effects of CBT and antidepressant
treatments.
Results from the current meta-analysis have relevant
implications for the palliative, curative, and prophylactic
treatment of individuals with major depression. Combined
with past research indicating the effectiveness of CBT in
the acute

(i.e., palliative) treatment of major depression

(e.g., Gloaguen et al.,

1998),

that CBT also offers curative,

the current results suggest
and potentially, prophylactic

benefits as participants treated with CBT evidenced
decreased risk for future depressive episodes. These results
suggest that treatment for major depression does not have to
be never-ending, but can be time-limited and future episodes
may even be prevented (Hollon et al.

1992). Although

existing evidence indicates that pharmacotherapy is
effective in the palliative treatment of depression, no
evidence exists that this effect lasts beyond
discontinuation (Hollon, Stewart,

& Strunk, 2006) . This
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finding is particularly noteworthy given the recurrent
nature of major depression (APAa,
Mueller et al.

2000; Hollon et al., 2006;

1999; Solomon et al.,

1997)

and substantial

deleterious effects of the disorder on the individual
(Hirschfeld et al., 2000 ; Hirschfeld & Davidson,

1988) .

These aforementioned findings in combination with the
present meta-analysis's results offer numerous potential
benefits in terms of enhanced cost-effectiveness, a
consideration that is of vital importance in an era of
managed health care that demands both effective and costeffective interventions

(Antonuccio et al.,

1997) .

Indeed,

the enduring effects of CBT in the current meta-analysis
suggest that this treatment may prove less expensive than
ADT in the long run (e.g., Hollon et al., 2005; Antonuccio
et al.). Not only might CBT offer long-term economic
benefits by reducing the need for maintenance or continued
treatment, but may also provide immediate benefits
decreased work absences,

(e.g.,

side effects, and suicides).

Still elusive are the potential mechanisms by which CBT
produces its enduring effect in individuals with major
depression. According to cognitive theory, cognitive therapy
results in improvement by facilitating change in information
processing and beliefs in the individual with depression
(Beck,

1987,

1991). Nevertheless,

this hypothesis has not
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received much empirical support

(Barber & DeRubeis,

1989) .

Although research repeatedly demonstrates that thinking
changes over the course of CBT, when these changes are
compared to the thinking changes that are observed in
depressed patients treated with antidepressants,

few

differences are observed between the groups, particularly
for automatic thoughts

(Imber et al.,

1990; Simons et al.,

1984 ; Weissman & Beck,

1978) . However, evidence does suggest

that CBT may produce greater changes in underlying beliefs
(e.g., core beliefs)
(e .g.

and information processing styles

attributional style; Hollon et al., 2005; Teasedale

et al. , 2001) , which do not appear to be stable
vulnerability factors, but remain largely dormant until
activated by a negative mood state or event

(i.e.,

diathesis-stress model or mood-state dependent hypothesis;
Hollon et al.,

1992b; Miranda & Persons,

1988). In their

comparison of CBT and pharmacotherapy, DeRubeis et al.
(1990)

found that CBT produced greater change in

attributional style and that much of the change occurred a
while after most of the changes in depressive severity were
observed (Hollon et al.,

1990) . Consequently, these results

suggest that changes in underlying beliefs and information
processing styles
in part,

(e.g., attributions) may account, at least

for the enduring and protective effects observed in
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those treated with CBT (Hollon et al., 2001) . Finally,

it

has been hypothesized that CBT's emphasis on teaching
depressed patients cognitive and behavioral strategies to
better manage their emotional reactions may be linked to the
enduring effects by in essence teaching the patient to be
her own therapist

(Barber & DeRubeis,

1989) .

Despite the common practice of early withdrawal from
medications in the reviewed studies, competent
pharmacotherapists would almost certainly not discontinue
antidepressant treatment after such a short treatment phase
(APA,

2000b; Depression Guideline Panel, 2000) .

Indeed, as

mentioned above treatment guidelines are increasingly
recommending maintenance on antidepressant treatment for a
minimum of six months following remission from the
depressive episode. Nevertheless, as Hollon et al.

(2006)

note, this practice of relatively early discontinuation of
antidepressant treatment in the research does provide an
effective demonstration of the enduring effects of CBT
following discontinuation when the two treatments are
compared. Despite the recommendation of continued
pharmacotherapy well beyond initial remission of the treated
episode,

studies repeatedly demonstrate a high prevalence of

premature discontinuation of antidepressant treatment across
multiple settings,

including mental health clinics
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(Katzelnick et al.,
Brevets, Kreisman,

1996; Simon et al.,
& Teitelbaum,

1998), primary care

et al . ,

1999; Simon et al.,

1999),

et al. ,

2006), Medicaid beneficiaries

samples with private insurance

2001; Fairman,

community samples
(Melfi et al.,

(Katzelnick et al.,

and those with managed pharmacy benefits

(Dunn
(Olfson
1998),

1996),

(Lewis et al.

2004). Even though treatment guidelines recommend
maintenance medications

it appears that in actual clinical

practice these recommendations are not upheld due to early
patient discontinuation. As such, the reviewed studies of
relatively brief pharmacotherapy may represent the real-life
use of antidepressants.
While the current meta-analysis drew upon numerous
sources of data previously ignored, a number of limitations
of the study must be noted. First, the significant
heterogeneity found among the studies included in the review
suggests that the studies represented populations differing
on more than simply treatment group. Potentially the most
important contributor to the variability was methodological
issues of the studies included in the analysis. Even though
the present meta-analysis substantially narrowed the sample
of studies included,

significant heterogeneity remained,

suggesting the importance of improved methodological rigor
and enhanced reporting of data in articles. To illustrate, a
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total of 19 different relapse criteria were used across the
23 articles included in the meta-analysis

and 6

(21%) of

the articles included 10 or less participants per group,
increasing the probability of random sampling error.
addressing these limitations

In

it is recommended that future

studies strive for greater standardization of utilized
measures and include larger sample sizes.
Second,

although the studies examining the long-term

effects of CBT and ADT have implemented a randomized and
controlled acute treatment phase,
all

the vast majority,

if not

of these studies have relied on a naturalistic follow

up phase. As such, possible differential ensuing factors,
such as attrition or further treatment, may have resulted in
disparate groups, making comparisons meaningless. In fact, a
number of the follow-up articles assessed for follow-up
treatment and briefly mentioned the additional treatment
sought by the participants

(e.g., Kovacs et al.,

1981) .

Based upon this observation of potential continued treatment
during follow-up,

it is possible that the treatments groups

represent distinct comparison groups that differ in more
than the initial acute treatment conditions. Furthermore,
the possible continued care would likely result in an
overestimation of the relapse prevention effect of the
treatment groups. Although the inability to control for
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these likely important covariates clearly limits the
findings of this meta-analysis,

excluding studies not

reporting follow-up treatment would have rendered the study
impossible due to too few studies. However, this meta
analysis may better represent the real-world or
generalizability of the findings. Important to note, these
studies included in the analyses represent only those
participants who sufficiently responded to acute phase
treatment, and thus, the results fail to account for those
depressed participants not meeting response criteria (i.e.,
those continuing to exhibit depressive symptoms). Future
studies would benefit from assessing for and reporting
treatment received by participants during the follow-up
phase as this would better allow for inclusion of the data
as a potential moderator or mediator variable in accounting
for relapse prevention, not to mention provide follow-up
data on those participants who continued to exhibit
depressive symptoms at treatment discontinuation.
In summary, the current meta-analysis found that
depressed individuals treated to early remission with CBT
evidenced decreased probability of relapse compared to those
treated with SSRI or TCA antidepressants. Although these
findings failed to reach significance at the final follow-up
point of 104 weeks, the trend clearly favored CBT as having
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greater protective effects post-treatment. These results
provide support for the hypothesis that CBT offers
differential benefits to its participants that contribute to
enduring effects. Given these findings of an enduring effect
for CBT, and to a lesser extent ADT, these findings have
significant implications for the effective long-term
management of depression.
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